First-Line Therapy Approved for Rare Lung Cancer | The CheckRare Brief Ep 7 by CheckRare Staff| Published on: Sep 15, 2026

This week, three developments highlight the rapidly changing rare disease treatment landscape: a Phase 3 setback in Angelman syndrome, continued competition in hereditary angioedema, and an FDA decision expanding access to a targeted lung cancer therapy. https://checkrare.com/first-line-therapy-approved-for-rare-lung-cancer-the-checkrare-brief-ep-7/